AngioDynamics (ANGO)
(Delayed Data from NSDQ)
$7.42 USD
-0.13 (-1.72%)
Updated Aug 27, 2024 03:59 PM ET
After-Market: $7.40 -0.02 (-0.27%) 6:04 PM ET
1-Strong Buy of 5 1
B Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.42 USD
-0.13 (-1.72%)
Updated Aug 27, 2024 03:59 PM ET
After-Market: $7.40 -0.02 (-0.27%) 6:04 PM ET
1-Strong Buy of 5 1
B Value B Growth F Momentum B VGM
Zacks News
Simulations Plus (SLP) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Simulations Plus' (SLP) third-quarter performance is likely to have gained from the healthy adoption of its solutions across various verticals amid continued macroeconomic weakness.
Are Options Traders Betting on a Big Move in AngioDynamics (ANGO) Stock?
by Zacks Equity Research
Investors need to pay close attention to AngioDynamics (ANGO) stock based on the movements in the options market lately.
Merit Medical (MMSI) Expands Suite via Buyouts, Revises FY23 View
by Zacks Equity Research
Merit Medical's (MMSI) latest addition to its portfolio is expected to significantly enhance patient outcomes.
New Strong Sell Stocks for May 18th
by Zacks Equity Research
ANGO, FPAY and BRDG have been added to the Zacks Rank #5 (Strong Sell) List on May 18, 2023.
Zacks.com featured highlights include Dutch Bros, Chegg, Impinj and AngioDynamics
by Zacks Equity Research
Dutch Bros, Chegg, Impinj and AngioDynamics are part of the Zacks Screen of the Week article.
Is the Options Market Predicting a Spike in AngioDynamics (ANGO) Stock?
by Zacks Equity Research
Investors need to pay close attention to AngioDynamics (ANGO) stock based on the movements in the options market lately.
Sell These 4 Toxic Stocks to Prevent Portfolio Losses
by Lavina Shahu
The basic understanding of toxic stocks can help investors avoid huge losses and derive maximum benefit from their portfolios. Some toxic stocks that investors may consider dumping are BROS, CHGG, PI and ANGO.
Zacks.com featured highlights include AngioDynamics, Definitive Healthcare, Casella Waste Systems and Enviva
by Zacks Equity Research
AngioDynamics, Definitive Healthcare, Casella Waste Systems and Enviva are part of the Zacks Screen of the Week article.
4 Toxic Stocks That Are Detrimental to Your Portfolio's Health
by Lavina Shahu
Accurately identifying toxic stocks and getting rid of them at the right time can protect your portfolio. You should sell ANGO, DH, CWST and EVA.
Implied Volatility Surging for AngioDynamics (ANGO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to AngioDynamics (ANGO) stock based on the movements in the options market lately.
AngioDynamics (ANGO) Q3 Earnings Lag Estimates, FY23 View Cut
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in third-quarter fiscal 2023.
AngioDynamics (ANGO) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of -200% and 2.28%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?
KORU Medical Systems Inc. (KRMD) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of 20% and 1.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Are Options Traders Betting on a Big Move in AngioDynamics (ANGO) Stock?
by Zacks Equity Research
Investors need to pay close attention to AngioDynamics (ANGO) stock based on the movements in the options market lately.
AngioDynamics (ANGO) Q2 Earnings, Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in second-quarter fiscal 2023.
AngioDynamics (ANGO) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of 200% and 1.65%, respectively, for the quarter ended November 2022. Do the numbers hold clues to what lies ahead for the stock?
SARTORIUS (SARTF) Surges 7.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
SARTORIUS (SARTF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
The Cooper Companies (COO) Q4 Earnings Miss Estimates
by Zacks Equity Research
The Cooper Companies (COO) delivered earnings and revenue surprises of -11% and 1.03%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?
Intuitive Surgical, Inc. (ISRG) Up 24.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
4 Toxic Stocks That May Stress You Out Amid Market Turmoil
by Rimmi Singhi
Just like identifying promising stocks, detecting toxic stocks and dumping them at the right time are crucial to safeguarding one's portfolio from big losses.
AngioDynamics (ANGO) Q1 Earnings, Revenues Lag Estimates
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in first-quarter fiscal 2023.
AngioDynamics (ANGO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of -200% and 1.99%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain AngioDynamics (ANGO) Stock Now
by Zacks Equity Research
AngioDynamics (ANGO) continues to benefit from strength in segments but forex remains a woe.
Why Is AngioDynamics (ANGO) Up 15.4% Since Last Earnings Report?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cardinal Health (CAH) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal fourth-quarter results are likely to reflect solid performance in the Pharmaceutical segment. However, inflation and supply chain constraints are likely to have continued.